Icon

REXULTI (nda205422)- (0.25MG,0.5MG,1MG,2MG,3MG,4MG)

BREXPIPRAZOLE OTSUKA
0.25MG,0.5MG,1MG,2MG,3MG,4MG
Yes No
2032-Oct-12 2020-Jul-10
None None
None No
REXULTI is an atypical antipsychotic indicated for: • Use as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD) in adults • Treatment of schizophrenia in adults and pediatric patients ages 13 years and older.
11 6 4
Total Other Developers 20
Drugs with Suitability No
0.25MG ** ** Up - -
0.5MG ** ** Up - -
1MG ** ** Up - -
2MG ** ** Up - -
3MG ** ** Up - -
4MG ** ** Up - -
NDA Sales Available Total Generic Sales Available
Yes 0
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country
****** ****** ****** *** ****** ****** ******* *********** **** **. *-*** /* ***** *** - **** **, *******, ******* ******, ***** (***) ***
****** ****** ****** *************** ******* ******* *********** **** ** ** & **, ******* ******* ******** **** *******-***** *.*. **. **, ***.: ******, ***.: ******, *********, ** ******, ***** (***) ***
****** ****** **** *** * ****** **** ******* *********** **** *, **. **.: ***, ***, *** & ***, ***** *********** ***, ********* *******, ************, ********* ******, ***** (***) ***

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search





Expired
to
Expired
to


Please contact contact@researchdelta.com to get more details.